Welcome

Investor Relations

Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Latest Investor Presentation Latest Earnings Presentation
(Updated September 9, 2021) (Updated August 5, 2021)
Stock Information
NASDAQNVAX
NASDAQNVAX
Recent News
Oct 15, 2021

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Vivek Shinde, M.D.,...

Oct 11, 2021

Full results from the PREVENT-19 pivotal Phase 3 trial of Novavax’ COVID-19 vaccine candidate have been posted to the medRxiv preprint server. The trial achieved its primary endpoint in which...

Oct 4, 2021

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment of Denny...

View All Press Releases

Events
Wednesday, September 29, 2021
8:40am - 9:10am EDT
Monday, September 13, 2021 - Wednesday, September 15, 2021
7:00am - 1:00pm EDT

Date: Monday, September 13, 2021 Time: Available on-demand starting at 7:00 a.m. Eastern Time (ET) Moderator: Vernon Bernardino Novavax participants: Gregory M. Glenn, M.D., President, Research...

Friday, September 10, 2021
2:00pm - 2:30pm EDT

Fireside Chat Date: Friday, September 10, 2021 Time: 2:00 – 2:30 p.m. Eastern Time (ET) Moderator: Jeffrey Hung Novavax participants: Gregory M. Glenn, M.D., President, Research and Development...

View All Events